Welcome to our dedicated page for Lensar news (Ticker: LNSR), a resource for investors and traders seeking the latest updates and insights on Lensar stock.
LENSAR, Inc. (Nasdaq: LNSR) is a commercial-stage medical device and global medical technology company focused on advanced laser systems for the treatment of cataracts and the management of astigmatism. News about LENSAR often centers on its ALLY Robotic Cataract Laser System, financial performance, and the company’s pending acquisition by Alcon Research, LLC.
Regular earnings releases provide updates on quarterly revenue, procedure volumes performed on LENSAR’s installed base of laser systems, and the mix between system sales and recurring revenue from procedures, leases, and service. These reports also discuss non-GAAP metrics such as EBITDA and Adjusted EBITDA, along with commentary on operational initiatives and utilization of the ALLY system in the United States and abroad.
Another recurring news theme is corporate and capital markets activity. LENSAR has announced a definitive merger agreement under which Alcon intends to acquire the company, including the ALLY Robotic Cataract Laser Treatment System, Streamline software technology, and the LENSAR legacy laser system. Subsequent updates describe stockholder approval of the merger proposal and ongoing regulatory review, including interactions with the U.S. Federal Trade Commission.
LENSAR also issues announcements related to equity compensation, such as inducement grants of restricted stock units and stock options to newly hired non-executive employees under its Employment Inducement Incentive Award Plan. These items provide insight into hiring and compensation practices. Investors and observers who follow LNSR news can use this page to review earnings releases, merger-related developments, and governance and compensation updates in one place.
LENSAR, Inc. (NASDAQ: LNSR) will announce its first quarter 2022 financial results before market open on May 9, 2022. A conference call and webcast will follow at 8:30 am ET, where management will discuss financial outcomes and corporate highlights. LENSAR specializes in advanced femtosecond laser systems for cataract treatment, integrating proprietary technologies aimed at enhancing surgical efficiency and visual outcomes.
LENSAR reported a 31% increase in 2021 revenue, reaching $34.5 million, driven by a 37% rise in procedure volume in Q4. The company submitted the ALLY™ 510(k) application to the FDA, aiming for a commercial launch later this year. While fourth-quarter revenue hit $11.2 million, the net loss improved to ($3.9 million) from ($6.8 million) year-over-year. Cash and cash equivalents were $31.6 million, a decrease from $40.6 million the previous year. Operating expenses declined due to lower stock-based compensation, despite increased R&D spending.
LENSAR, Inc. (NASDAQ: LNSR) announced FDA acceptance of its 510(k) submission for the ALLY™ Adaptive Cataract Treatment System. This submission marks a key milestone in its two-step commercialization strategy, aimed at enhancing cataract surgery with improved technology. The company plans to file an additional application for phacoemulsification features later in 2022. If cleared, LENSAR expects to launch the ALLY system in the second half of 2022, which may optimize surgical efficiency and patient outcomes, according to CEO Nick Curtis.
LENSAR, Inc. (LNSR), a medical technology company specializing in femtosecond laser systems for cataract treatment, will release its Q4 2021 and full year results on March 3, 2022, before the market opens. A conference call with management will follow at 8:30am ET the same day, accessible via phone or webcast through the company's website. LENSAR is committed to enhancing surgical outcomes with its innovative laser solutions, designed to improve efficiency and precision in cataract surgeries.
LENSAR, Inc. (NASDAQ: LNSR), a medical technology company specializing in femtosecond laser solutions for cataract treatment, will have CEO Nick Curtis participate in two investor conferences. The first is the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16 at 9:30 a.m. ET, and the second is the 11th Annual SVB Leerink Global Healthcare Conference on February 17 at 2:20 p.m. ET. The SVB Leerink chat can be accessed via LENSAR's website, and the recording will be available for a month post-event.
LENSAR, Inc. (NASDAQ: LNSR), a leader in medical technology for cataract treatment, has announced that CEO Nick Curtis will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on-demand starting January 10, 2022, at 7:00 a.m. Eastern Time, accessible through the Investors section of the company's website. LENSAR specializes in advanced femtosecond laser systems aimed at improving surgical outcomes for cataracts and corneal astigmatism, incorporating proprietary technologies for enhanced precision and efficiency.
LENSAR, Inc. (NASDAQ: LNSR) has announced that CEO Nick Curtis will present at two upcoming investor conferences. The first, the Piper Sandler 33rd Annual Virtual Healthcare Conference, will feature an on-demand presentation available starting November 22 at 10:00 a.m. ET. The second event, BTIG Ophthalmology Day, will include a fireside chat on November 30 at 8:00 a.m. ET. The Piper Sandler presentation can be accessed on the Company’s website, where it will be available for one month after being posted.
LENSAR, Inc. (NASDAQ: LNSR) announced two poster presentations accepted for the American Academy of Ophthalmology (AAO) Annual Meeting, scheduled for November 12-15, 2021. The presentations highlight the use of LENSAR's femtosecond laser technology in improving astigmatic outcomes during cataract surgery. The topics are:
- Femtosecond Laser Image Guided Corneal Arcuate Incisions for Managing Mild Keratometric Astigmatism in Cataract Surgery
- Toric IOL alignment with femtosecond laser capsular marks confirmed by intraoperative aberrometry
LENSAR (Nasdaq: LNSR) reported a 16% revenue increase for Q3 2021, totaling $8.3 million, driven by a 23% rise in procedure volumes compared to Q3 2020. Cash and cash equivalents stood at $32.3 million after $2.2 million in cash utilization for the quarter. The company anticipates a 510(k) filing for its ALLY™ Adaptive Cataract Treatment System in Q1 2022. However, the net loss for the quarter widened to $6.2 million, or ($0.65) per share. R&D expenses surged 59% to $3.2 million, primarily for the development of the ALLY system.
LENSAR, Inc. (NASDAQ: LNSR) will release its third quarter 2021 financial results on November 8, 2021, before market open. A conference call and webcast will follow at 8:30am ET on the same day to discuss these results and corporate highlights. LENSAR specializes in advanced femtosecond laser technologies for cataract treatment, aiming to improve visual outcomes for patients through its proprietary laser system.